•GTT shares were quoted at €205.00, up 3.27% on October 23, 2026.
•The company is targeting revenue of between €740 million and €780 million and EBITDA of between €490 million and €530 million in 2026, subject to no significant order delays or cancellations.
•The main order book covers estimated revenue of €300 million in the second half of 2026, €655 million in 2027 and €603 million in 2028.
•Coinbase made thousands of U.S. stocks and ETFs available for trading through agents, with 24/5 trading, fractional stock purchases starting at $1 and no commission.
•Coinbase launched its agent service on June 11, 2026, then announced the addition of stocks and ETFs on September 22, 2026.
•The x402 protocol processed more than 230 million transactions with a volume exceeding $54 million over slightly more than a year.
•The equal-weight S&P 500 ETF (RSP) is outperforming the market-cap weighted SPY by the largest margin since April 2009 as capital rotates out of AI stocks.
•The U.S. Food and Drug Administration approved a subcutaneous SKYRIZI induction regimen for adults with moderately to severely active Crohn’s disease on October 23, 2026.
•The induction dose is 720 mg at weeks 0, 2, 4 and 8; maintenance begins at week 12 and is repeated every 8 weeks.
•At week 12, clinical remission was 56% and endoscopic response was 43% with SKYRIZI, compared with 30% and 15% with placebo.
•Kemira expects 2026 earnings before interest, taxes, depreciation and amortisation to range between 400 and 500 million euros.
•First-half 2026 revenue fell 2% to 1,370.3 million euros, and earnings before interest, taxes, depreciation and amortisation declined 14% to 229.0 million euros.
•Kemira expects raw-material and logistics cost inflation to have an impact of about 100 million euros in 2026, with price increases covering about 50% of it.
•Flagstar reported net income of $12 million and net income attributable to common shareholders of $3 million, or $0.01 per diluted share, in the third quarter of 2026.
•Revenue reached $530 million, up 3% from the second quarter, while noninterest income fell 8% to $70 million.
•The provision for credit losses rose to $76 million from $18 million in the previous quarter.
•The committee announced the investigation on October 23, 2026, into the possibility that independent pharmacies were targeted with audits linked to their support for a reform bill.
•The committee requested documents, correspondence and briefings from CVS Caremark, Express Scripts and Optum Rx.
•The committee’s letter said an audit involving a drug costing $0.99 consumed hundreds of pharmacy work hours.
•Sallie Mae posted a loss attributable to common stock of $35.904 million in the third quarter of 2026, compared with earnings of $131.856 million a year earlier.
•The company cut its 2026 diluted earnings per share outlook to $1.95–$2.05 from $3.10–$3.20.
•Provisions for credit losses rose to $214 million, compared with $126 million in the previous quarter and $179 million a year earlier.
•Yara’s adjusted earnings before interest, taxes, depreciation and amortization were $675 million, about 10% below the $752 million estimate in the third quarter of 2026.
•Group sales were $4,478 million, above the $4,247 million estimate, while deliveries fell 4% year on year.
•Energy costs had a negative $165 million impact in the year-on-year comparison; pricing offset $95 million, while volume and mix reduced earnings by $40 million.
•Archax announced its adoption of Chainlink on October 19, 2026, to support the use of GOVY as programmable collateral.
•Chainlink data is intended to support lending, collateral and treasury management applications for banks, asset managers and decentralized finance users.
•Subscriptions and redemptions in supported stablecoins are available 24 hours a day, 365 days a year, according to Archax.
